Advertisement

Prolyl-hydroxylase domain inhibitors in chronic kidney disease, a promising alternative for erythropoiesis-stimulating agent

Published:April 20, 2020DOI:https://doi.org/10.1016/j.ejim.2020.04.033

      Highlights

      • ESA are commonly used to treat anemia in chronic kidney disease but meet several limits. Iron needs are elevated and cardio-vascular mortality may increase at high-dose.
      • Prolyl-hydroxylase domain is involved in hypoxia physiology and its inhibition leads to higher hemoglobin and lower hepcidin levels, decreasing iron needs. Oral PHD inhibitors will be soon available to treat CKD related anemia.
      • Many pathways are affected by PHD inhibition and data are lacking regarding their long term safety. For these reasons, longer studies are needed before using PHDi in clinical practice.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chen TK
        • Knicely DH
        • Grams ME
        Chronic kidney disease diagnosis and management: a review.
        JAMA. 01 2019; 322: 1294-1304
        • Inker LA
        • Grams ME
        • Levey AS
        • Coresh J
        • Cirillo M
        • Collins JF
        • et al.
        Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data meta-analysis in a global consortium.
        Am J Kidney Dis. 2019; 73: 206-217
        • Valderrábano F
        • Hörl WH
        • Macdougall IC
        • Rossert J
        • Rutkowski B
        • Wauters J-P
        PRE‐dialysis survey on anaemia management.
        Nephrol Dial Transplant. 2003; 18: 89-100
        • Locatelli F
        • Del Vecchio L
        • De Nicola R
        • Minutolo R.
        Are all erythropoiesis stimulating agents created equal ?.
        Nephrol Dial Transplant. 2020; (in press)
        • Locatelli F
        • Bárány P
        • Covic A
        • De Francisco A
        • Del Vecchio L
        • Goldsmith D
        • et al.
        Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement.
        Nephrol Dial Transplant. 2013; 28: 1346-1359
        • Hörl WH
        • Jacobs C
        • Macdougall IC
        • Valderrábano F
        • Parrondo I
        • Thompson K
        • et al.
        European best practice guidelines 14-16: inadequate response to epoetin.
        Nephrol Dial Transplant. 2000; 15 (Suppl): 43-50
        • Pfeffer MA
        • Burdmann EA
        • Chen C-Y
        • Cooper ME
        • de Zeeuw D
        • Eckardt K-U
        • et al.
        A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
        N Engl J Med. 2009; 361: 2019-2032
        • Pérez-García R
        • Varas J
        • Cives A
        • Martín-Malo A
        • Aljama P
        • Ramos R
        • et al.
        Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis.
        Nephrol Dial Transplant. 01 2018; 33: 690-699
        • Kidney Disease
        Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease.
        Kidney Int. 2012; 2 (Suppl): 279-335
        • Semenza GL
        • Agani F
        • Booth G
        • Forsythe J
        • Iyer N
        • Jiang BH
        • et al.
        Structural and functional analysis of hypoxia-inducible factor 1.
        Kidney Int. 1997; 51: 553-555
        • Wang GL
        • Jiang BH
        • Rue EA
        • Semenza GL
        Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
        Proc Natl Acad Sci U S A. 1995; 92: 5510-5514
        • Liu Q
        • Davidoff O
        • Niss K
        • Haase VH
        Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis.
        J Clin Invest. 2012; 122: 4635-4644
        • Besarab A
        • Provenzano R
        • Hertel J
        • Zabaneh R
        • Klaus SJ
        • Lee T
        • et al.
        Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
        Nephrol Dial Transplant. 2015; 30: 1665-1673
        • Provenzano R
        • Besarab A
        • Wright S
        • Dua S
        • Zeig S
        • Nguyen P
        • et al.
        Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study.
        Am J Kidney Dis Off J Natl Kidney Found. 2016; 67: 912-924
        • Chen N
        • Qian J
        • Chen J
        • Yu X
        • Mei C
        • Hao C
        • et al.
        Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
        Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2017; 32: 1373-1386
        • Chen N
        • Hao C
        • Peng X
        • Lin H
        • Yin A
        • Hao L
        • et al.
        Roxadustat for anemia in patients with kidney disease not receiving dialysis.
        N Engl J Med. 12 2019; 381: 1001-1010
        • Chen N
        • Hao C
        • Liu B-C
        • Lin H
        • Wang C
        • Xing C
        • et al.
        Roxadustat treatment for anemia in patients undergoing long-term dialysis.
        N Engl J Med. 12 2019; 381: 1011-1022
        • Yamamoto H
        • Taguchi M
        • Matsuda Y
        • Iekushi K
        • Yamada T
        • Akizawa T
        Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.
        BMJ Open. 14 2019; 9e026704
        • Singh AK
        • Milford E
        • Fishbane S
        • Keithi-Reddy SR
        Managing anemia in dialysis patients: hemoglobin cycling and overshoot.
        Kidney Int. 2008; 74: 679-683
        • Besarab A
        • Chernyavskaya E
        • Motylev I
        • Shutov E
        • Kumbar LM
        • Gurevich K
        • et al.
        Roxadustat (FG-4592): correction of anemia in incident dialysis patients.
        J Am Soc Nephrol JASN. 2016; 27: 1225-1233
        • Rahtu-Korpela L
        • Karsikas S
        • Hörkkö S
        • Blanco Sequeiros R
        • Lammentausta E
        • Mäkelä KA
        • et al.
        HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction.
        Diabetes. 2014; 63: 3324-3333
        • Jokilehto T
        • Jaakkola PM.
        The role of HIF prolyl hydroxylases in tumour growth.
        J Cell Mol Med. 2010; 14: 758-770
        • Yeşilbaş O
        • Yıldız N
        • Ö Baykan
        • Alpay H
        Is hepcidin related with anemia and bone mineral metabolism in children with non-dialysis chronic kidney disease?.
        Turk Pediatri Arsivi. 2019; 54: 238-245
        • Lefere S
        • Van Steenkiste C
        • Verhelst X
        • Van Vlierberghe H
        • Devisscher L
        • Geerts A
        Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease.
        Cell Mol Life Sci CMLS. 2016; 73: 3419-3431
        • Gonzalez FJ
        • Xie C
        • Jiang C
        The role of hypoxia-inducible factors in metabolic diseases.
        Nat Rev Endocrinol. 2018; 15: 21-32
        • Laitakari A
        • Ollonen T
        • Kietzmann T
        • Walkinshaw G
        • Mennerich D
        • Izzi V
        • et al.
        Systemic inactivation of hypoxia-inducible factor prolyl 4-hydroxylase 2 in mice protects from alcohol-induced fatty liver disease.
        Redox Biol. 2019; 22101145
        • Taniguchi CM
        • Finger EC
        • Krieg AJ
        • Wu C
        • Diep AN
        • LaGory EL
        • et al.
        Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes.
        Nat Med. 2013; 19: 1325-1330
        • Schäfer ST
        • Frede S
        • Winning S
        • Bick A
        • Roshangar P
        • Fandrey J
        • et al.
        Hypoxia-inducible factor and target gene expression are decreased in patients with sepsis: prospective observational clinical and cellular studies.
        Anesthesiology. 2013; 118: 1426-1436
        • Messa P
        • Cappellini MD.
        A new approach for anemia in kidney disease.
        Eur J Int Med. 2019; 71: 1-3https://doi.org/10.1016/j.ejim.2019.10.035
        • Wanner C
        • Krane V
        • März W
        • Olschewski M
        • Mann JFE
        • Ruf G
        • et al.
        Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
        N Engl J Med. 2005; 353: 238-248
        • De Brito-Ashurst I
        • Varagunam M
        • Raftery M J.
        • Yaqoob M M.
        Bicarbonate supplementation slows progression of CKD and improves nutritional status.
        JASN. 2009; 20: 2075-2084
        • Fouque D
        • Roth H
        • Darné B
        • Bouchet J-L
        • Daugas E
        • B Drüeke T
        • Hannedouche T
        • Jean G
        • M London G
        Achievement of 2009 and 2017 KDIGO mineral and bone targets and survival in a French cohort of chronic kidney disease Stages 4 and 5 non-dialysis patients.
        Clin Kidney J. 2018; : 710-719